HC Wainwright Forecasts Pharming Group Q1 Earnings

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Pharming Group in a report released on Thursday, March 12th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of $0.00 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s Q2 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.12 EPS and FY2026 earnings at $0.35 EPS.

Several other brokerages also recently issued reports on PHAR. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Oppenheimer reiterated an “outperform” rating and set a $41.00 target price (down from $42.00) on shares of Pharming Group in a research report on Friday. Finally, Zacks Research lowered shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Pharming Group Price Performance

Shares of PHAR stock opened at $14.51 on Friday. Pharming Group has a 52 week low of $7.50 and a 52 week high of $21.34. The stock has a market capitalization of $1.02 billion, a PE ratio of 1,451.00 and a beta of 0.04. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. The stock’s fifty day moving average is $17.21 and its 200-day moving average is $16.06.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The business had revenue of $106.50 million for the quarter, compared to analyst estimates of $111.76 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.12%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC grew its position in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after buying an additional 28,615 shares during the period. Millennium Management LLC acquired a new position in Pharming Group in the fourth quarter valued at approximately $360,000. SmartHarvest Portfolios LLC bought a new position in Pharming Group in the fourth quarter valued at approximately $224,000. Finally, EverSource Wealth Advisors LLC acquired a new stake in Pharming Group during the 2nd quarter worth $32,000. Institutional investors own 0.03% of the company’s stock.

Key Stories Impacting Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Company set a 2026 revenue target of $405M–$425M, citing growth from Joenja and RUCONEST as primary drivers — this provides clear growth levers for next year and supports upside if execution meets targets. Pharming outlines $405M–$425M 2026 revenue target
• Positive Sentiment: Company reported full-year and Q4 2025 revenue growth and positive cash flow and reaffirmed 2026 guidance — fundamentals showing improving cash generation can reduce funding risk and support valuation. Pharming Group reports fourth quarter and full year 2025 financial results
• Positive Sentiment: Oppenheimer reiterated an “Outperform” rating with a $41 price target (slightly trimmed), signaling continued bullish analyst conviction and implying substantial upside from current levels. Oppenheimer reaffirms outperform on PHAR
• Neutral Sentiment: HC Wainwright maintains a Buy rating and $37 target but lowered FY2026 EPS from $0.49 to $0.35 — the firm still expects material 2026 profitability, but the cut shows some model uncertainty around timing and magnitude of margin expansion. HC Wainwright updates estimates for PHAR
• Negative Sentiment: Q4 results missed expectations: revenue $106.5M vs. analyst ~$111.8M and EPS $0.07 vs. $0.15 expected — the quarter’s misses likely triggered the intraday sell-off despite upbeat guidance. Pharming Q4 2025 press release

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.